AI-Enabled Pathology: De-risking Oncology Drug Development

We’re excited to share that Mindpeak has been recognized by Ada Ventures as part of a select group of innovators building the next-generation infrastructure for global health.

In their recent spotlight, Ada Ventures highlights the urgency of rethinking healthcare systems to meet the demands of a longer-living, more complex global population. Their vision spans five critical pillars of bio‑infrastructure—from lab automation to talent development, with Mindpeak featured under "Patient Data Platforms" for our contributions to secure, inclusive, and actionable health data.

At Mindpeak, we’re proud to play a pivotal role in this transformation:

Advancing Precision Diagnostics

Our AI software brings cutting-edge biomarker translation directly into pathology workflows—supporting clinicians in identifying breast, lung, and other cancers with speed and precision.

Making Patient Data Clinically Useful

Unlike conventional data platforms, we focus on real-time, tissue-based insights that are immediately actionable in the clinic. This enables faster decision-making and more equitable access to personalized care.

Scaling Globally

With deployments across 20+ countries and partnerships with leading labs, we’re not just imagining the future, we’re delivering it, one slide at a time.

We’re honored to be included alongside visionary companies across the healthcare and life sciences ecosystem. Together, we’re helping build a world where AI, data, and infrastructure truly serve everyone.

🔗 Read Ada Ventures’ full bio‑infrastructure spotlight

‍

We’re thrilled that Mindpeak GmbH has been featured in the AlbionVC HLTH Europe HealthTech Market Map 2025, which includes leading companies across digital care and digital pharma in Europe!

Explore the European HealthTech landscape in AlbionVC’s interactive map: https://lnkd.in/da6H84sJ

‍

‍

Mindpeak GmbH is looking back at an unforgettable experience at this year’s ASCO2025!

‍Seeing our work presented in front of 2,000+ experts on the world’s leading oncology stage was more than an honor - it was a defining moment in Mindpeak’s mission to transform cancer diagnostics with AI.

This year stood out as we reached key milestones - most notably, unveiling the transformative results of our collaboration with AstraZeneca, driving the evolution of breast cancer therapies.

Key Highlights:

AI-powered HER2-ultralow detection: Our technology, deployed in one of the world’s largest clinical studies, enabled HER2-ultralow detection at scale - supporting AstraZeneca's Enhertu clinical program.

Clinical Impact: As seen in our session, our AI was instrumental in generating reproducible, high-quality data that contributes to more personalized treatment strategies for breast cancer patients.

Digital pathology at center stage: With our tech featured across multiple sessions and posters, Mindpeak's vision of accessible, automated cancer diagnostics is becoming a reality.‍

#ASCO2025 wasn't just about showcasing innovation - it was about proving real-world impact.

We’re building AI that scales, adapts, and empowers clinicians worldwide. The response we received confirmed: we’re solving the right problems, in the right way.

A heartfelt thank you to our partners at AstraZeneca, to the many labs and clinicians who made this possible, and to the incredible team at Mindpeak. Your dedication and ambition are the heartbeat of this movement.

Let’s keep pushing forward - the future of AI-driven cancer care is happening now.